Evidence map›Paper›PMID 41488505›Full record

ArticleRSC advances2025

Synthesis, characterization, and anticancer potential of novel NHC ligands and their selenium complexes: a combined

Boutheina Boualia, Abd El-Krim Sandeli, Enes Evren, İsmail Özdemir, Hüseyin Karci, Muhammed Dündar, İlknur Özdemir, Nevin Gürbüz, Ahmet Koç, Houssem Boulebd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Boutheina BoualiaThe Molecular and Structural Environmental Chemistry Research Unit, Faculty of Exact Sciences, Brother's Mentouri Constantine 1 University Constantine Algeria.
Abd El-Krim SandeliPharmaceutical Sciences Research Center (CRSP) Constantine 25000 Algeria.ORCID https://orcid.org/0009-0009-8590-567X
Enes Evrenİnönü University Drug Administration and Research Center 44280-Malatya Turkey.ORCID https://orcid.org/0000-0002-7571-410X
İsmail Özdemirİnönü University Drug Administration and Research Center 44280-Malatya Turkey.ORCID https://orcid.org/0000-0001-6325-0216
Hüseyin Karciİnönü University Drug Administration and Research Center 44280-Malatya Turkey.ORCID https://orcid.org/0000-0002-5709-1623
Muhammed DündarInönü University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics 44280-Malatya Turkey.ORCID https://orcid.org/0000-0001-6509-2012
İlknur Özdemirİnönü University Drug Administration and Research Center 44280-Malatya Turkey.ORCID https://orcid.org/0000-0002-8566-8979
Nevin Gürbüzİnönü University Drug Administration and Research Center 44280-Malatya Turkey.ORCID https://orcid.org/0000-0003-3201-3597
Ahmet Koçİnönü University, Faculty of Medicine, Department of Medical Genetics 44280-Malatya Turkey.ORCID https://orcid.org/0000-0003-3484-2137
Houssem BoulebdLaboratory of Synthesis of Molecules with Biological Interest, Frères Mentouri Constantine 1 University Constantine 25017 Algeria boulebd.houssem@umc.edu.dz.ORCID https://orcid.org/0000-0002-7727-8583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report herein the efficient synthesis of new benzimidazolium salts (A1-A6) and their corresponding selenium-NHC complexes (B1-B6), along with the evaluation of their cytotoxicity profiles against two cancer cell lines (HCT116 and SH-SY5Y) and one normal cell line (BEAS-2B). The findings revealed that the benzimidazolium salts (A1-A6) exhibited significantly higher cytotoxicity toward all tested cell lines compared to their selenium derivatives (B1-B6). Among them, compounds A3, A4, and A5 showed the most potent cytotoxic effects, with IC

Identifiers

PMID41488505
PMCPMC12757842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.